LON:GNS Genus (GNS) Share Price, News & Analysis GBX 2,015 -75.00 (-3.59%) As of 05/7/2025 12:15 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsHeadlinesInsider TradesBuy This Stock About Genus Stock (LON:GNS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Genus alerts:Sign Up Key Stats Today's Range 1,986▼ 2,08050-Day Range 1,548▼ 2,084.2452-Week Range 1,424▼ 2,155Volume134,095 shsAverage Volume278,399 shsMarket Capitalization£1.32 billionP/E Ratio167.03Dividend Yield1.59%Price TargetGBX 2,150Consensus RatingBuy Company OverviewGenus plc operates as an animal genetics company in North America, Latin America, the United Kingdom, rest of Europe, the Middle East, Russia, Africa, and Asia. The company operates through three segments: Genus PIC, Genus ABS, and Genus Research and Development. It sells breeding pigs and semen to breed pigs with various characteristics for pork production under the PIC brand. The company also sells bull semen and embryos to breed calves with various characteristics for milk and beef production under the ABS, Genus, and Bovec brands. In addition, it offers technical services to farmers. The company was incorporated in 1994 and is based in Basingstoke, the United Kingdom.Read More… Genus Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks16th Percentile Overall ScoreGNS MarketRank™: Genus scored higher than 16% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.5 / 5Analyst RatingBuy Consensus RatingGenus has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageGenus has only been the subject of 1 research reports in the past 90 days.Read more about Genus' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Genus is 167.03, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 22.09.Price to Earnings Ratio vs. SectorThe P/E ratio of Genus is 167.03, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 24.88.Price to Earnings Growth RatioGenus has a PEG Ratio of 2.87. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioGenus has a P/B Ratio of 2.43. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for GNS. Dividend0.8 / 5Dividend StrengthWeak Dividend YieldGenus pays a meaningful dividend of 1.69%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthGenus does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Genus is 265.25%. Payout ratios above 75% are not desirable because they may not be sustainable.Read more about Genus' dividend. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for GNS. News and Social Media2.4 / 5News Sentiment0.39 News SentimentGenus has a news sentiment score of 0.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.64 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Genus this week, compared to 1 article on an average week.Search Interest6 people have searched for GNS on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Genus insiders have sold more of their company's stock than they have bought. Specifically, they have bought GBX 0 in company stock and sold £345,628.77 in company stock.Percentage Held by InsidersOnly 0.75% of the stock of Genus is held by insiders.Percentage Held by Institutions77.79% of the stock of Genus is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Genus' insider trading history. Receive GNS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Genus and its competitors with MarketBeat's FREE daily newsletter. Email Address GNS Stock News HeadlinesGenus (LON:GNS) Given Buy Rating at Shore CapitalMay 2, 2025 | americanbankingnews.comUK shares advance as investors react to wave of corporate earningsApril 30, 2025 | msn.comElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they gotten away with it, the Fed and U.S. banks could have seized control of our financial lives forever. But Trump stopped them cold on January 23rd, 2025, when he outlawed CBDCs… Paving the way for Elon Musk's secret master plan.May 8, 2025 | Brownstone Research (Ad)Genus rockets 27% in the FTSE 250! Should I buy this UK stock?April 30, 2025 | msn.comFour Brands Making Their Debut at Watches and Wonders 2025April 2, 2025 | msn.comKepler Capital Keeps Their Buy Rating on Genus plc (GNS)March 5, 2025 | markets.businessinsider.comGenus' Projections Indicate Future Payments May Be UnsustainableMarch 2, 2025 | finance.yahoo.comGenus' (LON:GNS) earnings trajectory could turn positive as the stock advances 3.9% this past weekFebruary 6, 2025 | uk.finance.yahoo.comSee More Headlines GNS Stock Analysis - Frequently Asked Questions How have GNS shares performed this year? Genus' stock was trading at GBX 1,550 at the beginning of the year. Since then, GNS shares have increased by 30.0% and is now trading at GBX 2,015. View the best growth stocks for 2025 here. How were Genus' earnings last quarter? Genus plc (LON:GNS) issued its earnings results on Thursday, February, 27th. The company reported $39.80 earnings per share (EPS) for the quarter. Genus had a trailing twelve-month return on equity of 1.41% and a net margin of 1.18%. Read the conference call transcript. How do I buy shares of Genus? Shares of GNS stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of Genus own? Based on aggregate information from My MarketBeat watchlists, some other companies that Genus investors own include Meta Platforms (META), Lloyds Banking Group (LLOY), Rolls-Royce Holdings plc (RR.L), AstraZeneca (AZN), Barclays (BARC), BP (BP) and Clinigen Group (CLIN). Company Calendar Last Earnings2/27/2025Today5/07/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryPersonal Services Current SymbolLON:GNS CIKN/A Webwww.genusplc.com Phone+44-1256-347100FaxN/AEmployees480Year FoundedN/APrice Target and Rating Average Stock Price TargetGBX 2,150 High Stock Price TargetGBX 2,150 Low Stock Price TargetGBX 2,150 Potential Upside/Downside+6.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)GBX 12.06 Trailing P/E Ratio167.03 Forward P/E Ratio28.39 P/E Growth2.87Net Income£7.87 million Net Margins1.18% Pretax MarginN/A Return on Equity1.41% Return on Assets3.31% Debt Debt-to-Equity Ratio53.12 Current Ratio1.80 Quick Ratio1.08 Sales & Book Value Annual Sales£666.67 million Price / Sales1.98 Cash FlowGBX 39.85 per share Price / Cash Flow50.56 Book ValueGBX 827.95 per share Price / Book2.43Miscellaneous Outstanding Shares65,483,478Free FloatN/AMarket Cap£1.32 billion OptionableNot Optionable Beta0.37 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.Get This Free Report This page (LON:GNS) was last updated on 5/8/2025 by MarketBeat.com Staff From Our PartnersTrump to redistribute trillions of dollars Seeing how the media and other analysts are covering Trump’s actions – it’s laughable. At least it would be la...Porter & Company | Sponsored270x more lucrative than NVIDIA???270x more lucrative than NVIDIA??? If you've missed out on NVIDIA's recent 1,600% run... Don't worry. ...Behind the Markets | SponsoredMost traders are panicking. We’re cashing inMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...Stansberry Research | SponsoredVanishing BenefitsWhat would you do if your next Social Security check simply never arrived? If you called and the line was d...Investors Alley | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredUrgent News from my Oceanfront Estate Near Mar-a-LagoFor 40 years, I've had a front-row seat to history's greatest wealth creation events. I spotted Microsoft a...InvestorPlace | SponsoredElon’s Been UpgradedThe New Elon Musk is officially stepping back from his day-to-day duties with DOGE. At least, that's the s...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genus plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Genus With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.